Cipla Acquires 100% Stake in Inzpera Healthsciences for ₹110.65 Crore

Cipla Limited has announced the acquisition of **Inzpera Healthsciences Limited**, a Mumbai-based paediatric pharmaceutical and wellness company, for an **enterprise value of ₹120 crore**. The total **purchase consideration stands at approximately ₹110.65 crore**, subject to closing adjustments. The deal will be completed within a month from signing. Founded in **2016**, Inzpera focuses on developing, manufacturing, and marketing **differentiated paediatric and wellness products** in India. The company reported a turnover of **₹26.75 crore in FY25**, growing steadily from **₹20.76 crore in FY23**. Cipla stated that the acquisition is a **strategic move to enhance its paediatric and wellness portfolio**, leveraging its robust distribution network and operational strength to drive scalability and market penetration. The transaction will be settled entirely in **cash** and will make Inzpera a **wholly owned subsidiary** of Cipla. --- 📊 *Source: Company filing (03 Nov 2025)* 📍 *CMP: —* **Disclaimer:** This article is for informational purposes only and not investment advice. **Follow for more:** @AFS Trading Edge ⚡